放射性125I粒子治疗复发性甲状腺癌的临床疗效观察  

The Clinical Efficacy of Radioactive 125I Particles in the Treatment of Recurrent Thyroid Cancer

作　　者：喻岳超 徐俊马 刘智 刘雨 YU Yue-chao;XU Jun-ma;LIU Zhi;LIU Yu(The General Hospital of Xuzhou Mining Group, Department of Nuclear Medicine, the Second Affiliated Hospital ofXuzhou Medical University, Xuzhou 221006, China)

机构地区：[1]徐州矿务集团总医院徐州医科大学第二附属医院核医学科

出　　处：《标记免疫分析与临床》2019年第8期1332-1333,1360,共3页Labeled Immunoassays and Clinical Medicine

摘　　要：目的探讨应用放射性 125I粒子治疗复发性甲状腺癌的临床疗效。方法分析本院收治的32例复发性甲状腺癌患者的临床资料,所有患者均接受放射性 125I粒子治疗,评价患者的预后效果。结果治疗后6个月采用CT复查肿瘤变化,多数复发性甲状腺癌患者的瘤体不同程度缩小,完全缓解率为37.50%,部分缓解率为43.75%,总缓解率为81.25%,观察期内病人全部生存。治疗后2、4、6月血清Tg水平与治疗前相比差异有统计学意义( P <0.05)。结论对复发性甲状腺癌患者采取放射性 125I粒子治疗能显著提升疾病的治疗效果,促进瘤体缩小,且未出现严重并发症。Objective To investigate the clinical efficacy of radioactive 125I particles in the treatment of recurrent thyroid cancer. Methods The clinical data of 32 patients with recurrent thyroid cancer in our hospital were retrospectively analyzed, all of whom were treated with radioactive 125I particles. We evaluated the prognosis of these patients in this study. Results CT re- examination of tumor changes 6 months after the treatment showed that most patients with recurrent thyroid cancer had reduced tumor size at varying degrees, with complete remission rate of 34.38%, partial remission rate of 53.12%, and total remission rate of 87.50%.All patients survived. Conclusion Radioactive 125I seed therapy for patients with recurrent thyroid cancer can significantly improve the therapeutic effect of the disease, promote tumor shrinkage, and no serious complications occur.

关 键 词：放射性 125I粒子 复发性甲状腺癌 临床疗效 

分 类 号：R736.1[医药卫生—肿瘤] R730.55[医药卫生—临床医学]